ID   WM139
AC   CVCL_C266
SY   WM-139; WM 139; EST71
DR   cancercelllines; CVCL_C266
DR   Cosmic; 1047651
DR   Cosmic; 2163801
DR   ESTDAB; ESTDAB-071
DR   GEO; GSM156024
DR   IARC_TP53; 26078
DR   Progenetix; CVCL_C266
DR   Wikidata; Q54994174
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=19340423;
RX   PubMed=23851445;
CC   Part of: Wistar Institute melanoma cell line collection.
CC   HLA typing: A*32:01,32:01; B*14:01,14:01; C*08:02,08:02; DPB1*02:01:02,02:01:02; DQB1*02:01,02:01 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17260012).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Val82fs (c.243_244ins19) (p.Arg96fs, c.286_287ins19); Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Omics: Array-based CGH.
ST   Source(s): ESTDAB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9
ST   D3S1358: 14,17
ST   D5S818: 9,11
ST   D7S820: 9,11
ST   FGA: 20,25
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 17,19
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 20
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//